In this study, safety and tolerability of multiple ascending doses of TRV734, and single doses of TRV734 125 mg following various administration paradigms, in healthy subjects were evaluated. In both parts of the study, TRV734 was generally well tolerated with no serious adverse events. ...
The initial results from Design’s Phase 1 multiple ascending dose trial underscore the promise of DT-216 as a potential disease-modifying treatment for FA. The favorable systemic safety profile and FXN response support continued development of DT-216. However, the company has elected to complete ...
You can select single ring type, repeated ring type,orascendingringtype. sonimtech.com sonimtech.com 您可以选择单独的铃声类型,重复铃 声类型或者渐进式铃声类型。 sonimtech.com sonimtech.com Press the manual override ontheDoseValve B solenoid ...
A Single Ascending Dose and Multiple Ascending Dose Phase I Study of PXS-5382A Administered Orally,Pharmaxis,Interventional,Phase 1
Phase 1 Single and Multiple Ascending Dose Study of CAT-2003, a Novel Activator of Lipoprotein Lipase, Decreases Postprandial Tr risk of requiring revascularization in this population. Priordata on this subject have been conflicting, and no similarstudies exist among patients treated with optimal ...
A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis.###Tailoring the magnetic and pharmacokinetic properties of iron oxide magnetic particle imaging tracers.##...
Study Design: Randomized, double-blind, placebo-controlled, combined single and multiple ascending dose phase I study. Healthy males (age 18–65 years, body mass index 18–?2) were randomized to four of five dalcetrapib doses (2100,2700, 3300, 3900 or 4500 mg) or placebo, with ≥10 ...
Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease View LargeDownload Figure 1. Patient Flow During the Multiple-Ascending Dose (MAD) and Long-Term Extension (LTE) Periods View LargeDownload Eligible patients were randomly assigned in a 3:1 ...
Study Design: Randomized, double-blind, placebo-controlled, combined single and multiple ascending dose phase I study. Healthy males (age 18–65 years, body mass index 18–?2) were randomized to four of five dalcetrapib doses (2100,2700, 3300, 3900 or 4500 mg) or placebo, with ≥10 ...
Zealand Pharma A/S announced results from Part 1 of a multiple ascending dose trial for ZP8396, the company's long-acting amylin analog with potential for the management of overweight and obesity.